How to Cite
Abstract
ENDOTHELIAL LIPASE AS NEW DIAGNOSTIC MARKER OF NON-ALCOHOLIC FATTY LIVER DISEASE IN HYPERTENSIVE SUBJECTS (review)
Bashkirova A.D
Non-alcoholic fatty liver disease (NAFLD) and hypertension are among the most common diseases in the world. One of the negative factors contributing to the formation of cardiovascular risk in patients with NAFLD affected with hypertension is the low level of HDL cholesterol in which metabolism endothelial lipase (EL) plays a leading role. Therefore, it is very relevant and expedient to study the various aspects of the use of EL to diagnose NAFLD and determe treatment strategy in patients with NAFLD and hypertension.
Key words: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hypertension, endothelial lipase, lipid metabolism, overweight.
ЕНДОТЕЛІАЛЬНА ЛІПАЗА ЯК НОВИЙ ДІАГНОСТИЧНИЙ МАРКЕР НЕАЛКОГОЛЬНИЙ ЖИРОВОЇ ХВОРОБИ ПЕЧІНКИ (НАЖХП) У ОСІБ З ГІПЕРТЕНЗІЄЮ (огляд)
Башкірова А.Д.
НАЖХП і гіпертонічна хвороба є одними з найпоширеніших хвороб у світі. Одним з несприятливих факторів, що сприяють формуванню кардіоваскулярного ризику у пацієнтів з НАЖБП на тлі гіпертонічної хвороби, є низький рівень холестерину ЛПВЩ, в метаболізмі якого грає провідну роль активність ендотеліальної ліпази. Тому досить актуальним і доцільним є вивчення різних аспектів використання ЕЛ для діагностики НАЖБП з подальшим визначенням лікувальної тактики у хворих НАЖХП на тлі ГХ.
Ключові слова: неалкогольна жирова хвороба печінки, неалкогольний стеатогепатит, гіпертонічна хвороба, ендотеліальналіпаза, ліпіднийобмін, надлишковамасатіла .
ЭНДОТЕЛИАЛЬНАЯ ЛИПАЗА КАК НОВЫЙ ДИАГНОСТИЧЕСКИЙ МАРКЕР НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ (НАЖБП)У ЛИЦ С ГИПЕРТЕНЗИЕЙ (обзор)
Башкирова А.Д.
НАЖБП и гипертоническая болезнь являются одними из самых распространенных болезней в мире. Одним из неблагоприятных факторов, способствующих формированию кардиоваскулярного риска у пациентов с НАЖБП на фоне гипертонической болезни, является низкий уровень холестерина ЛПВП, в метаболизме которого играет ведущую роль активность эндотелиальной липазы. Поэтому весьма актуальным и целесообразным является изучение различных аспектов использования ЭЛ для диагностики НАЖБП с последующим определением лечебной тактики у больных НАЖБП на фоне ГБ.
Ключевые слова: неалкогольная жировая болезнь печени, неалкогольный стеатогепатит, гипертоническая болезнь, эндотелиальная липаза, липидный обмен, избыточная масса тела.
References
Lee Y.J., Shim J.Y., Moon B.S., Shin Y.H., Jung D.H., …, Lee H.R. (2012). The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci. V.57:196-203.
Kosobyan E.P., Smirnova O.M. (2010). Sovremennyie kontseptsii patogeneza nealkogolnoy zhirovoy bolezni pecheni. Saharnyiy diabet. Vol.1:55-64.
Liu H., Lu H-Y. (2014). Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol. V.20(26):8407-8415.
Alkhouri N., Kistangari G., Campbell C., Lopez R., Zein N.N., Feldstein A.E. (2012). Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis. Hepatology. V.55:331.
Dam-Larsen S., Becker U., Franzmann M.B., Larsen K., Christoffersen P., Bendtsen F. (2009). Final results of a long-term, clinical follow-up in fatty liver patients. Scandinavian Journal of Gastroenterology. V.44(10):1236-1243.
Alkhouri N., Tamimi T.A.R., Yerian L., Lopez R., Zein N.N., Feldstein A.E. (2010). The inflamed liver and atherosclerosis: a Link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Digestive Diseases and Sciences. V.55(9:2644-2650.
Chon YE, Kim KJ, Jung KS, Kim SU, Park JY, …, Han KH. (2016). The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter. Yonsei Med J. 57(4):885-92. doi: 10.3349/ymj.2016.57.4.885. PubMed Central PMCID: PMC4951464.
Ramilli S., Pretolani S., Muscari A., Pacelli B., Arienti V. (2009). Carotid lesions in outpatients with nonalcoholic fatty liver disease. World Journal of Gastroenterology. V.15(38):4770-4774.
Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, …, Zanchetti A. (2007). ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 16(3):135-232. PubMed PMID: 17846925.
Haffner SM. (2000). Obesity and the metabolic syndrome: the San Antonio Heart Study. Br J Nutr. 83 Suppl 1:S67-70. PubMed PMID: 10889794.
Gerasimova A.S., Oleynikov V.E. (2010). Osobennosti medikamentoznoy korrektsii arterialьnoy gipertenzii pri metabolicheskom sindrome. Zhurnal Izvestiya vyisshih uchebnyih zavedeniy. Povolzhskiy region. V.1:106-119.
Madan SA, John F, Pyrsopoulos N, Pitchumoni CS. (2015). Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: meta-analysis. Eur J Gastroenterol Hepatol. 27(11):1237-48. doi: 10.1097/MEG.0000000000000429. PubMed PMID: 26193052.
Suzuki T., Hirata K., Elkind M.S. et al. (2008). Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Nordhern Manhattan Study (NOMAS). Am. Heart.J. Vol. 156:405.
Schindhelm R.K., Dekker J.M., Nijpels G. et al. (2007). Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. V.191(2):391-396.
Wang C.C., Tseng Y.F. et al. (2009). Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. V.24(8):1411-1416.
Ioannou G.N., Weiss N.S., Boyko E.J., Mozaffarian D., Lee S.P. (2006). Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. V.43(5):1145-1151.
Monami M., Bardini G., Lamanna C. et al. (2008). Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. V.57(3):387-392.
Lopez-Suarez A., Guerrero M., Elvira-Gonzalez J., Beltran-Robles M., Canas-Hormigo F., Bascunana-Quirell A. (2011). Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individ-uals from the general population with normal levels of alanine aminotransferase. European Journal of Gastroenterology and Hepatology. V.23(11):1011-1017.
Feitosa M.F., Reiner A.P., Wojczynski M.K., Graff M., North K.E., Carr J.J., Borecki I.B. (2013). Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis. 227:420-424.
De Filippis A.P., Blaha M.J., Martin S.S., Reed R.M., Jones S.R., …, Budoff M.J. (2013). Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. V.227:429-436.
Feitosa M.F., Reiner, M.K. Wojczynski, M. Graff, K.E. North, …, Borecki I.B. (2013). Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease Atherosclerosis. V.227:420-424.
Akın L., Kurtoglu S., Yikilmaz A., Kendirci M., Elmalı F., Mazicioglu M. (2013). Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation. Acta Paediatr. V.102:107-113.
Catena C., Bernardi S., Sabato N., Grillo A., Ermani M., …, Fallo F. (2013). Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. Nutr Metab Cardiovasc Dis. V.23:389-393.
Fracanzani A.L., Burdick L., Raselli S. et al. (2008). Carotid artery intima-media thickness in nonalcoholic fatty liver disease. American Journal of Medicine. V.121(1):72-78.
Cakır E., Ozbek M., Colak N., Cakal E., Delıbaşi T. (2012). Is NAFLD an independent risk factor for increased IMT in T2DM? Minerva Endocrinol. V.37:187-193.
Colak Y., Senates E., Yesil A., Yilmaz Y., Ozturk O., ..., Ulasoglu C. (2013). Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. V.43:100-107.
Bhatia L.S., Curzen N.P., Byrne C.D. (2012). Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol. V.27:420-428.
Butorova L.I., Kadnikova L.I., Kalashnikova M.A. (2014). Lekarstvennyie povrezhdeniya pecheniu patsientov s metabolicheskim sindromomi nealkogolnoy zhirovoy boleznyu pecheni:novyie vozmozhnosti profilaktiki i lecheniya. Meditsinskie novosti. V.8(239):41-47.
Bueverov A.O., Bogomolov P.O. (2012). «Tsitokinovyiy vzryiv» i progressirovanie nealkogolnogo steatogepatita. Klinicheskie perspektivyi gastroenterologii, gepatologii. V.5:12-18.
Heuer M., Kaiser G.M., Kahraman A., Banysch M., Saner F.H.,…, Treckmann J.W. (2012). Liver transplantation in non-alcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion. V.86:107-113.
Coracina A., Gaiani S., Cosma A., Pellizzari P., Pizzi C., …, Tessari P. (2012). No association between the degree of liver steatosis and early signs of vasculopathy in T2DM. Nutr Metab Cardiovasc Dis. V.22:11-12.
de Carvalho S.C., Muniz M.T., Siqueira M.D., Siqueira E.R., Gomes A.V., …, Pereira L.M. (2013). Plasmatic higher levels of homocysteine in non-alcoholic fatty liver disease (NAFLD). Nutr J. V.12:37.
Dogru T., Genc H., Tapan S., Ercin C.N., Ors F., …, Kurt I. (2012). Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes Res Clin Pract. V.96:47-52.
Kaur J.A. (2014). Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract. V.2014:943162.
Morioka, T., Emoto, M., Yamazaki, Y., Kawano, N., Imamura, S., Numaguchi, R., … Inaba, M. (2014). Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes. Cardiovascular Diabetology, 13, 10. http://doi.org/10.1186/1475-2840-13-10
Statsenko M.E., Turkina S.V., Evtereva E.D. (2012). Metabolicheskaya terapiya meldoniem: vozmozhnosti primeneniya v lechenii hronicheskoy serdechnoy nedostatochnosti u bolnyih s metabolicheskim sindromom. Consilium medicum. – 2012. V. 15:81-86.
Paradis, M.-E., & Lamarche, B. (2006). Endothelial lipase: Its role in cardiovascular disease. The Canadian Journal of Cardiology, 22(Suppl B), 31B–34B.
DiMarco, D. M., & Fernandez, M. L. (2015). The Regulation of Reverse Cholesterol Transport and Cellular Cholesterol Homeostasis by MicroRNAs. Biology, 4(3), 494–511. http://doi.org/10.3390/biology4030494
Miksztowicz V, McCoy MG, Schreier L, Cacciagiú L, Elbert A, …, Berg G. (2012). Endothelial lipase activity predicts high-density lipoprotein catabolism in hemodialysis: novel phospholipase assay in postheparin human plasma. Arterioscler Thromb Vasc Biol. 32(12):3033-40. doi: 10.1161/ATVBAHA.112.300110.
Shiu, S. W., Zhou, H., Wong, Y., & Tan, K. C. (2010). Endothelial lipase and reverse cholesterol transport in type 2 diabetes mellitus. Journal of Diabetes Investigation, 1(3), 111–116. http://doi.org/10.1111/j.2040-1124.2010.00016.x
Masakatsu Shimizu, Kenji Kanazawa, Ken-ichi Hirata et al. (2007). Endothelial Lipase Gene Polymorphism is Associated With Acute Myocardial Infarction, Independently of High-Density Lipoprotein-Cholesterol Levels. Circ J. V.71: 842 –846.
Badellino KO, Wolfe M, Dykhouse J, Rohatgi A, Reilly M, Rader DJ. (2004). Endothelial lipase is upregulated by inflammatory mediators and correlated with low рL levels seen in metabolic syndrome. Circulation. V.110:52.
Paradis M.E., Badellino K.O., Rader D.J., et al. (2004). Endothelial lipase, obesity and the metabolic syndrome. Arterioscler Thromb Vasc Biol. V.24:E6.
Razzaghi H, Tempczyk-Russell A, Haubold K, Santorico SA, Shokati T, et al. (2013) Genetic and Structure-Function Studies of Missense Mutations in Human Endothelial Lipase. PLoS ONE 8(3): e55716. doi:10.1371/journal.pone.0055716.
Griffon, N., Jin, W., Petty, T. J., Millar, J., Badellino, K. O., Saven, J. G., … Rader, D. J. (2009). Identification of the Active Form of Endothelial Lipase, a Homodimer in a Head-to-Tail Conformation. The Journal of Biological Chemistry, 284(35), 23322–23330. http://doi.org/10.1074/jbc.M109.037002
"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.
Copyright Agreement
1. This Agreement on the transfer of rights to use the work from the Co-authors to the publisher (hereinafter the Agreement) is concluded between all the Co-authors of the work, represented by the Corresponding Author, and Kharkiv National Medical University (hereinafter the University), represented by an authorized representative of the Editorial Board of scientific journals (hereinafter the Editorial Board).
2. This Agreement is an accession agreement within the meaning of clause 1 of Article 634 of the Civil Code of Ukraine: that is, a contract, "the terms of which are established by one of the parties in forms or other standard forms, which can be concluded only by joining the other party to the proposed contract as a whole. The other party cannot offer its terms of the contract." The party that established the terms of this contract is the University.
3. If there is more than one author, the authors choose the Corresponding Author, who communicates with the Editorial Board on his own behalf and on behalf of all Co-authors regarding the publication of a written work of a scientific nature (article or review, hereinafter referred to as the Work).
4. The contract begins from the moment of submission of the manuscript of the Work by the Corresponding Author to the Editorial Board, which confirms the following:
4.1. all Co-authors of the Work are familiar with and agree with its content, at all stages of reviewing and editing the manuscript and the existence of the published Work;
4.2. all Co-authors of the Work are familiar with and agree to the terms of this Agreement.
5. The published Work is in electronic form in public access on the websites of the University and any websites and electronic databases in which the Work is posted by the University and is available to readers under the terms of the "Creative Commons" license (Attribution NonCommercial Sharealike 4.0 International)" or more free licenses "Creative Commons 4.0".
6. The Corresponding Author transfers, and the University receives, the non-exclusive property right to use the Work by placing the latter on the University's websites for the entire term of copyright. The University participates in the creation of the final version of the Work by reviewing and editing the manuscript of the article or review provided to the Editorial Board by the Corresponding Author, translating the Work into any languages. For the participation of the University in the finalization of the Work, the Co-authors agree to pay the invoice issued to them by the University, if such payment is provided by the University. The size and procedure of such payment are not the subject of this contract.
7. The University has the right to reproduce the Work or its parts in electronic and printed forms, to make copies, permanent archival storage of the Work, distribution of the Work on the Internet, repositories, scientometric databases, commercial networks, including for monetary compensation from third parties.
8. The co-authors guarantee that the manuscript of the Work does not use works whose copyright belongs to third parties.
9. The authors of the Work guarantee that at the time of submission of the manuscript of the Work to the Editorial Board, the property rights to the Work belong only to them, neither in whole nor in part have they been transferred to anyone (not alienated), they are not the subject of a lien, litigation or claims by third parties.
10. The Work may not be posted on the University's website if it violates a person's right to the privacy of his personal and family life, harms public order and health.
11. The work may be withdrawn by the Editorial Board from the University websites, libraries and electronic databases where it was placed by the Editorial Board, in cases of detection of violations of the ethics of the authors and researchers, without any compensation for the losses of the Co-authors. At the time of submission of the manuscript to the Editorial Board and all stages of its editing and review, the manuscript must not have already been published or submitted to other editorial offices.
12. The right transferred under this Agreement extends to the territory of Ukraine and foreign countries.
13. The rights of Co-authors include the requirement to indicate their names on all copies of the Work or during any public use or public mention of the Work; the requirement to preserve the integrity of the Work; legal opposition to any distortion or other encroachment on the Work, which may harm the honor and reputation of the Co-authors.
14. Co-authors have the right to control their personal non-property rights by familiarizing themselves with the text (content) and form of the Work before its publication on the University's website, when transferring it to a printing company for reproduction or when using the Work in other ways.
15. The Co-authors, in addition to the property rights not transferred under this Agreement and taking into account the non-exclusive nature of the rights transferred under this Agreement, retain the property rights to finalize the Work and to use certain parts of the Work in other works created by the Co-authors.
16. The Co-authors are obliged to notify the Editorial Board of all errors in the Work, discovered by them independently after the publication of the Work, and to take all measures to eliminate such errors as soon as possible.
17. The University undertakes to indicate the names of the Co-authors on all copies of the Work during any public use of the Work. The list of Co-authors may be shortened according to the rules for the formation of bibliographic descriptions determined by the University or third parties.
18. The University undertakes not to violate the integrity of the Work, to agree with the Corresponding Author on all changes made to the Work during processing and editing.
19. In case of violation of their obligations under this Agreement, its parties bear the responsibility defined by this Agreement and the current legislation of Ukraine. All disputes under the Agreement are resolved through negotiations, and if the negotiations do not resolve the dispute – in the courts of the city of Kharkiv.
20. The parties are not responsible for the violation of their obligations under this Agreement, if it occurred through no fault of theirs. The party is considered innocent if it proves that it has taken all measures dependent on it for the proper fulfillment of the obligation.
21. The Co-authors are responsible for the truthfulness of the facts, quotes, references to legislative and regulatory acts, other official documentation, the scientific validity of the Work, all types of responsibility to third parties who have claimed their rights to the Work. The co-authors reimburse the University for all costs caused by claims of third parties for infringement of copyright and other rights to the Work, as well as additional material costs related to the elimination of identified defects.